Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)


İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S. , Basaran G., Saip P., et al.

BREAST CANCER, cilt.22, ss.480-485, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 22 Konu: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s12282-013-0506-y
  • Dergi Adı: BREAST CANCER
  • Sayfa Sayısı: ss.480-485

Özet

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.